Scandion Oncology Q3 2022: Back to the basics
Research Update
2022-11-16
11:36
Redeye comments on Scandion Oncology’s Q3 2022 report, some one month after the company has recruited the first of up to 36 patients to its phase II CORIST part 3 dose-finding arm. We adjust our estimates and fair value range to reflect current capital market conditions.
CB
JU
Christian Binder
Johan Unnerus
Disclosures and disclaimers